Huntington's Disease Market: Future Demand and Top Key Players Analysis | 2029

 Whether you’re expanding or optimizing within the huntington’s disease industry, this report offers the clarity and context needed for confident decision-making.

 

 What Is The Current Outlook For The Huntington’s Disease Market By 2025?
 The huntington’s disease market size has grown rapidly in recent years. It will grow from $0.47 billion in 2024 to $0.55 billion in 2025 at a compound annual growth rate (CAGR) of 16.0%. The growth in the historic period can be attributed to increasing awareness about chronic diseases, increasing government awareness programs, rising government initiatives to spread awareness for huntington’s disease, increase in geriatric population, and rising research on genetic disorders.
 
 The huntington’s disease market size is expected to see rapid growth in the next few years. It will grow to $1.05 billion in 2029 at a compound annual growth rate (CAGR) of 17.7%. The growth in the forecast period can be attributed to rising prevalence of neurological disorders, increasing public awareness, rising healthcare expenditure, growing research and development investments, and growing clinical research activities. Major trends in the forecast period include adoption of the novel drug, numerous drug development, emergence of new technologies, technological advancements, and demand for advanced products.
 
 Get your free sample today:
 https://www.thebusinessresearchcompany.com/sample.aspx?id=22008&type=smp
 
 What Are The Key Driving Factors For The Growth Of The Huntington’s Disease Market?
 The rising prevalence of neurological disorders is expected to propel the growth of the huntington’s disease market going forward. Neurological disorders are medical conditions that affect the brain, spinal cord, and nerves, leading to symptoms such as movement, coordination, sensory, or cognitive impairments. The increase in neurological disorders can be attributed to factors such as aging populations, environmental toxins, lifestyle changes, improved diagnostic capabilities, and genetic predispositions, which help detect and identify more cases. Huntington’s disease is a neurodegenerative disorder caused by a genetic mutation, leading to motor dysfunction, cognitive decline, and psychiatric symptoms, progressively worsening over time. For instance, in March 2023, according to the Alzheimer’s Association, a US-based nonprofit voluntary health organization, an estimated 6.7 million Americans aged 65 and older currently have Alzheimer’s dementia. Without medical breakthroughs to prevent, slow, or cure the disease, this number could rise to 13.8 million by 2060. Therefore, the rising prevalence of neurological disorders is driving the growth of the huntington’s disease market.
 
 Global Huntington’s Disease Market Report Segmentation
 The huntington’s diseasemarket covered in this report is segmented — 
 
 1) By Treatment Type: Symptomatic Therapy; Disease-Modifying Therapy; Other Treatment Types
 2) By Diagnosis: Magnetic Resonance Imaging (MRI); Computed Tomography (CT) Scan; Genetic Testing; Other Diagnosis
 3) By Route of Administration: Oral; Parenteral; Other Routes Of Administration
 4) By Distribution Channel: Hospital Pharmacy; Online Pharmacy; Retail Pharmacy
 5) By End User: Hospitals; Homecare; Specialty Clinics; Other End Users
 
 Subsegments:
 
 1) By Symptomatic Therapy: Antipsychotics; Antidepressants; Mood Stabilizers; Muscle Relaxants
 2) By Disease-Modifying Therapy: Gene Silencing Therapies; Stem Cell Therapy; Neuroprotective Agents
 3) By Other Treatment Types: Physical Therapy; Occupational Therapy; Speech Therapy
 
 Huntington’s Disease Market Emerging Trends And Opportunities
 Major companies operating in the huntington’s disease market are focusing on developing innovative solutions, such as oral small molecule drugs to treat symptoms and slow disease progression. An oral small molecule drug is a low-molecular-weight compound that can be administered orally and is designed to interact with biological targets, such as proteins or enzymes, to treat diseases. For instance, in September 2024, PTC Therapeutics Inc., a US-based pharmaceutical company, received Fast Track designation from the U.S. Food and Drug Administration (USFDA) for its PTC518 program aimed at treating Huntington’s disease. This designation is intended for therapies that address significant unmet medical needs, highlighting the potential of PTC518 as a disease-modifying treatment for patients suffering from this genetic disorder.
 
 Who Are The Leading Players In The Huntington’s Disease Market?
 Major companies operating in the huntington’s disease market are Novartis AG, Eli Lilly and Company, Teva Pharmaceutical Industries Ltd, Bausch Health Companies Inc., Sun Pharmaceutical Industries Ltd., Apotex Inc, Ipsen S.A., Vertex Pharmaceuticals Incorporated, H. Lundbeck A/S, Dr. Reddy’s Laboratories Ltd., Hikma Pharmaceuticals PLC, Lupin Limited., Neurocrine Biosciences Inc., Alnylam Pharmaceuticals Inc, PTC Therapeutics Inc., Annexon Inc., Voyager Therapeutics Inc., Stealth BioTherapeutics Corp., Vaccinex Inc., SOM Biotech S.L., Alterity Therapeutics Limited, Medesis pharma SA. 
 
 View the full huntington’s disease market report here:
 https://www.thebusinessresearchcompany.com/report/huntingtons-disease-global-market-report
 
 Which Region Is Projected To Hold The Largest Market Share In The Global Huntington’s Disease Market By 2029?
 North America was the largest region in the huntington’s disease market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the huntington’s disease market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
 
 Contact Us:
 
 The Business Research Company 
 
 https://thebusinessresearchcompany.com/ 
 
 Americas +1 310–496–7795
 Asia +44 7882 955267 & +91 8897263534
 Europe +44 7882 955267 
 
 Email: info@tbrc.info 
 
 
 Follow Us On:
 
 LinkedIn: https://in.linkedin.com/company/the-business-research-company